DCP
NBIX icon

Distillate Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Distillate Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.3M Buy
93,261
+722
+0.8% +$95.8K 0.65% 90
2025
Q4 		$13.1M Sell
92,539
-1,877
-2% -$272K 0.68% 89
2025
Q3 		$13.3M Sell
94,416
-27,198
-22% -$3.69M 0.69% 86
2025
Q2 		$15.3M Sell
121,614
-8,175
-6% -$938K 0.82% 58
2025
Q1 		$14.4M Buy
+129,789
New +$16.4M 0.74% 69

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Distillate Capital Partners's NBIX Position: Q1 2026 in Review

Distillate Capital Partners increased its Neurocrine Biosciences (NBIX) stake by 0.78% in Q1 2026, buying an estimated $95.8K and bringing the position to 93,261 shares worth $12.3M. The position accounts for 0.65% of the portfolio, ranked #90.

Distillate Capital Partners first reported a position in NBIX in Q1 2025 and has held it in 5 quarters since. The position peaked at $15.3M in Q2 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Distillate Capital Partners held 93,261 shares of Neurocrine Biosciences worth $12.3M as of Q1 2026.
  • Distillate Capital Partners bought 722 Neurocrine Biosciences shares in Q1 2026, an estimated $95.8K.
  • Neurocrine Biosciences made up 0.65% of Distillate Capital Partners's portfolio in Q1 2026, its #90 holding.
  • Distillate Capital Partners first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 5 quarters since.
  • Distillate Capital Partners's Neurocrine Biosciences position peaked at $15.3M in Q2 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Distillate Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.